脂蛋白(a)对主髂动脉粥样硬化病变腔内治疗后临床结局的预测价值
本研究纳入189例因主髂动脉闭塞性疾病行腔内治疗的外周动脉疾病患者,按血清脂蛋白(a)水平分为≤40 mg/dL组(135例)和>40 mg/dL组(54例)。中位随访33个月,高脂蛋白(a)组无主要不良肢体事件生存率显著更低(55.6% vs 85.2%,p<0.001),高脂蛋白(a)是MALE的独立预测因子(HR 2.80,95%CI 1.44-5.45,p=0.003)。
要点
- 高脂蛋白(a)(>40 mg/dL)与主髂动脉EVT后MALE风险升高独立相关。
- 高脂蛋白(a)组无MALE生存率显著低于低值组(55.6% vs 85.2%)。
- 血液透析和高脂蛋白(a)均为MALE的独立预测因子。
核心结论
- 高脂蛋白(a)水平与主髂动脉病变患者EVT后主要不良肢体事件发生率升高相关。
研究设计与样本
- 回顾性队列研究,纳入189例连续接受主髂动脉闭塞性疾病EVT的外周动脉疾病患者,中位年龄72岁,男性160例。
- 按入院时血清脂蛋白(a)水平≤40 mg/dL(低值组,n=135)或>40 mg/dL(高值组,n=54)分组。
- 中位随访33个月(四分位距11-54个月),分析MALE发生率及预测因素。
主要发现
- 随访期间44例(23.3%)发生MALE。
- 高值组无MALE生存率显著低于低值组(55.6% vs 85.2%,p<0.001)。
- Cox比例风险分析显示,血液透析(HR 2.23,95%CI 1.04-4.78,p=0.039)和高脂蛋白(a)水平(HR 2.80,95%CI 1.44-5.45,p=0.003)是EVT后MALE的独立预测因子。
临床怎么用
- 对于接受主髂动脉EVT的患者,可考虑检测血清脂蛋白(a)水平以辅助风险分层。
- 高脂蛋白(a)(>40 mg/dL)或合并血液透析的患者可能需要更密切的术后随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the usefulness of serum lipoprotein(a) as a biomarker of clinical outcomes after endovascular therapy (EVT) for atherosclerotic aortoiliac lesions. METHODS: Serum lipoprotein(a) concentrations were measured at admission in 189 consecutive patients (median age 72 years; 160 men) with peripheral artery disease who underwent EVT for aortoiliac occlusive disease. The patients were dichotomized into 2 groups based on serum lipoprotein(a) levels ≤40 mg/dL (LOW; n=135) or >40 mg/dL (HIGH; n=54). After EVT, the incidences of major adverse limb events (MALE) were analyzed. Predictors of MALE were sought with a Cox proportional hazards analysis; results are presented as the hazard ratio (HR) and 95% confidence interval. RESULTS: At the median follow-up of 33 months (interquartile range 11, 54), MALE occurred in 44 (23.3%) patients. The MALE-free survival estimate was significantly lower in patients in the HIGH group (55.6% vs 85.2%, p<0.001). Independent predictors of MALE after EVT were hemodialysis (HR 2.23, 95% CI 1.04 to 4.78, p=0.039) and high lipoprotein(a) levels (HR 2.80, 95% CI 1.44 to 5.45, p=0.003). CONCLUSION: High lipoprotein(a) levels were associated with a higher incidence of MALE after EVT for patients with aortoiliac lesions.
引用
- Hishikari K, Hikita H, Nakamura S, et al. Usefulness of Lipoprotein(a) for Predicting Clinical Outcomes After Endovascular Therapy for Aortoiliac Atherosclerotic Lesions. J Endovasc Ther. 2017. PMID: 28830274. doi:10.1177/1526602817728068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。